Allergy Rounds With Dr. Autumn

HCPLive has launched Allergy Rounds with Dr. Autumn, a monthly allergy and immunology podcast hosted by Autumn Burnette, MD, an allergist and immunologist at Howard University in Washington, DC, focused on new approvals, pipeline therapies, and what they mean for practice.

Each episode will start with recent headlines and examine what they mean for prescribing decisions the following week. New approvals often raise practical questions, including access, comparisons with current therapy, and whether insurers will require step therapy first.

“Rarely do patients come in with just one issue, and quite often I have to consult my colleagues in other specialties,” Burnette said. “Everyone brings what they know, and the plan gets better.”

Topics on the Allergy Rounds Podcast Agenda

Burnette will sit down once a month with fellow allergists and colleagues from other specialties, including pulmonologists and dermatologists. As an allergist, she sees conditions spanning respiratory, skin, gastrointestinal, and hematologic disease.

Planned topics include emerging hereditary angioedema (HAE) therapies and gene research, newly approved triple therapies for asthma, and newer nonsteroidal options in atopic dermatitis. The show will also examine payer barriers standing between patients and treatment.

Hereditary Angioedema Series Opens the Podcast

The first full episode will focus on HAE and how far care has come in 2026. Burnette will review the treatment landscape, discuss updated guidelines, address unmet needs, and look at the pipeline beyond 2026.

The World Allergy Organization (WAO) published its 2025 guidelines for the classification, diagnosis, and treatment of HAE in 2026.¹ The guidelines call for a treat-to-target approach to long-term prophylaxis, reassessed at least annually through shared decision-making, and on-demand treatment access for every patient with confirmed HAE.¹ The FDA also accepted with priority review the biologics license application for lonvoguran ziclumeran (lonvo-z), a single-dose in vivo CRISPR therapy.²

New episodes of Allergy Rounds with Dr. Autumn post monthly in audio and video formats on major podcast platforms and hcplive.com.

Editor’s note: Reported disclosures include Ionis Pharmaceuticals, ARS Pharmaceuticals Operations, GENZYME CORPORATION, Regeneron Healthcare Solutions, Takeda Pharmaceuticals, Organon LLC, Lilly USA, LLC, CSL Behring, AstraZeneca Pharmaceuticals LP, and more.

References

1. Vázquez DO, Giavina-Bianchi P, Josviack D, et al. The 2025 WAO guidelines for the classification, diagnosis, and treatment of hereditary angioedema, with consideration of worldwide disparities. World Allergy Organ J. 2026;19(5):101335. doi:10.1016/j.waojou.2026.101335

2. HCPLive. Lonvo-z BLA accepted by FDA with priority review for HAE. https://www.hcplive.com/view/lonvo-z-bla-accepted-fda-priority-review-hae. Published September 8, 2026. Accessed November 9, 2026.